Mecamylamine does not precipitate withdrawal in cigarette smokers

Research output: Contribution to journalArticle

Abstract

Mecamylamine is an antihypertensive that acts via nicotinic antagonism and has been suggested as an aid in smoking cessation. Nicotine dependent patients may not accept mecamylamine if it precipitates withdrawal, as it does in nicotine dependent rats. This study examined mecamylamine's effects using procedures designed to measure precipitated withdrawal symptoms in humans. Ten cigarette smokers (mean of 37.5 cigarettes/day) and ten non tobacco-using subjects participated in three 6-h sessions. After a 2-h baseline period in which smokers smoked one cigarette every 30 min, oral mecamylamine (0, 10, or 20 mg randomly ordered across sessions) was administered (double-blind). No smoking was allowed for the remainder of the session. Mecamylamine reduced blood pressure and increased heart rate relative to placebo in both the smokers and the non-tobacco users. No reliable direct subjective effects of mecamylamine were observed. Smokers' subjective reports of cigarette craving and tobacco withdrawal increased, and DSST performance was disrupted over the last 4 h of each session. Effects were independent of dose (placebo versus active). These results suggest that up to 20 mg mecamylamine will not precipitate nicotine withdrawal and that this medication would be acceptable for use in smoking cessation.

Original languageEnglish (US)
Pages (from-to)328-336
Number of pages9
JournalPsychopharmacology
Volume127
Issue number1-2
DOIs
StatePublished - Jun 1996

Fingerprint

Mecamylamine
Tobacco Products
Nicotine
Smoking Cessation
Tobacco
Placebos
Substance Withdrawal Syndrome
Antihypertensive Agents
Heart Rate
Smoking
Blood Pressure

Keywords

  • Antagonist-precipitated withdrawal
  • Antagonists
  • Mecamylamine
  • Nicotine
  • Physical dependence
  • Withdrawal

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mecamylamine does not precipitate withdrawal in cigarette smokers. / Eissenberg, Thomas; Griffiths, Roland R; Stitzer, Maxine L.

In: Psychopharmacology, Vol. 127, No. 1-2, 06.1996, p. 328-336.

Research output: Contribution to journalArticle

@article{ac0421c709604d15b7befebd52dc69bf,
title = "Mecamylamine does not precipitate withdrawal in cigarette smokers",
abstract = "Mecamylamine is an antihypertensive that acts via nicotinic antagonism and has been suggested as an aid in smoking cessation. Nicotine dependent patients may not accept mecamylamine if it precipitates withdrawal, as it does in nicotine dependent rats. This study examined mecamylamine's effects using procedures designed to measure precipitated withdrawal symptoms in humans. Ten cigarette smokers (mean of 37.5 cigarettes/day) and ten non tobacco-using subjects participated in three 6-h sessions. After a 2-h baseline period in which smokers smoked one cigarette every 30 min, oral mecamylamine (0, 10, or 20 mg randomly ordered across sessions) was administered (double-blind). No smoking was allowed for the remainder of the session. Mecamylamine reduced blood pressure and increased heart rate relative to placebo in both the smokers and the non-tobacco users. No reliable direct subjective effects of mecamylamine were observed. Smokers' subjective reports of cigarette craving and tobacco withdrawal increased, and DSST performance was disrupted over the last 4 h of each session. Effects were independent of dose (placebo versus active). These results suggest that up to 20 mg mecamylamine will not precipitate nicotine withdrawal and that this medication would be acceptable for use in smoking cessation.",
keywords = "Antagonist-precipitated withdrawal, Antagonists, Mecamylamine, Nicotine, Physical dependence, Withdrawal",
author = "Thomas Eissenberg and Griffiths, {Roland R} and Stitzer, {Maxine L}",
year = "1996",
month = "6",
doi = "10.1007/BF02806011",
language = "English (US)",
volume = "127",
pages = "328--336",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - Mecamylamine does not precipitate withdrawal in cigarette smokers

AU - Eissenberg, Thomas

AU - Griffiths, Roland R

AU - Stitzer, Maxine L

PY - 1996/6

Y1 - 1996/6

N2 - Mecamylamine is an antihypertensive that acts via nicotinic antagonism and has been suggested as an aid in smoking cessation. Nicotine dependent patients may not accept mecamylamine if it precipitates withdrawal, as it does in nicotine dependent rats. This study examined mecamylamine's effects using procedures designed to measure precipitated withdrawal symptoms in humans. Ten cigarette smokers (mean of 37.5 cigarettes/day) and ten non tobacco-using subjects participated in three 6-h sessions. After a 2-h baseline period in which smokers smoked one cigarette every 30 min, oral mecamylamine (0, 10, or 20 mg randomly ordered across sessions) was administered (double-blind). No smoking was allowed for the remainder of the session. Mecamylamine reduced blood pressure and increased heart rate relative to placebo in both the smokers and the non-tobacco users. No reliable direct subjective effects of mecamylamine were observed. Smokers' subjective reports of cigarette craving and tobacco withdrawal increased, and DSST performance was disrupted over the last 4 h of each session. Effects were independent of dose (placebo versus active). These results suggest that up to 20 mg mecamylamine will not precipitate nicotine withdrawal and that this medication would be acceptable for use in smoking cessation.

AB - Mecamylamine is an antihypertensive that acts via nicotinic antagonism and has been suggested as an aid in smoking cessation. Nicotine dependent patients may not accept mecamylamine if it precipitates withdrawal, as it does in nicotine dependent rats. This study examined mecamylamine's effects using procedures designed to measure precipitated withdrawal symptoms in humans. Ten cigarette smokers (mean of 37.5 cigarettes/day) and ten non tobacco-using subjects participated in three 6-h sessions. After a 2-h baseline period in which smokers smoked one cigarette every 30 min, oral mecamylamine (0, 10, or 20 mg randomly ordered across sessions) was administered (double-blind). No smoking was allowed for the remainder of the session. Mecamylamine reduced blood pressure and increased heart rate relative to placebo in both the smokers and the non-tobacco users. No reliable direct subjective effects of mecamylamine were observed. Smokers' subjective reports of cigarette craving and tobacco withdrawal increased, and DSST performance was disrupted over the last 4 h of each session. Effects were independent of dose (placebo versus active). These results suggest that up to 20 mg mecamylamine will not precipitate nicotine withdrawal and that this medication would be acceptable for use in smoking cessation.

KW - Antagonist-precipitated withdrawal

KW - Antagonists

KW - Mecamylamine

KW - Nicotine

KW - Physical dependence

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=0029972206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029972206&partnerID=8YFLogxK

U2 - 10.1007/BF02806011

DO - 10.1007/BF02806011

M3 - Article

VL - 127

SP - 328

EP - 336

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1-2

ER -